Skip To Main Content
Nick Paul Taylor on Muck Rack

Nick Paul Taylor

Verified
Manchester
As seen in: Yahoo Entertainment, Yahoo Life, Yahoo News, Clinical Rehabilitation, Yahoo Finance, Flipboard, Yahoo Sports, Yahoo, The West Australian, EIN News and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Nick Paul

Contact Nick Paul, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Steris inks $2.1B Xodus buyout to expand consumables portfolio

|
By Nick Paul Taylor Verified
| MedTech Dive Verified
Steris said Monday it struck a $2.1 billion deal to acquire Xodus Medical for its portfolio of consumable healthcare products. Xodus’ portfolio includes Pink Pad patient-positioning products and the See Sharp laparoscopic cleaning and defogging device. The company expects annual sales to hit $245 million this year.
Open in Who Shared Issue with article?

BioNTech’s mRNA cancer vaccine fails phase 3 test, significantly denting analysts’ confidence

|
By Nick Paul Taylor Verified
| Fierce Biotech Verified
A phase 2/3 clinical trial of BioNTech’s mRNA cancer immunotherapy BNT113 has missed one of its dual primary endpoints. But with immature overall survival (OS) data offering a path to redemption, the German biotech is continuing to track patients in the metastatic head and neck cancer study. Hopes for BioNTech’s mRNA cancer immunotherapy pipeline jumped in August, when Merck & Co. and Moderna’s phase 3 data reset expectations for the wider field.
Open in Who Shared Issue with article?

Roche inks $1.2B deal with China's Rona to enter emerging ALK7 obesity race

|
By Nick Paul Taylor Verified
| Fierce Biotech Verified
Roche has committed $100 million in upfront and near-term payments to license Rona Therapeutics’ ALK7 drug candidate, joining Alnylam, Arrowhead Pharmaceuticals, GSK and Novo in an emerging obesity niche. Years of research has shown ALK7, a protein encoded by the ACVR1C gene, is preferentially expressed in adipose tissue and involved in lipid metabolism.
Open in Who Shared Issue with article?
See all 10,727 licensed articles (11,181 Total)